Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy by itself, according to researchers from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center. The results, published in Cancer Discovery, prime the combination strategy for future clinical trials.
đ Full Story

Charleston White Explains How Men Are Becoming More Like Women!
- Decreased levels of TDP-43 gene may be contributing to neurodegenerative diseases like Alzheimer's and ALS
- The 2023 Geminid Meteor Shower: A Spectacular Sky Show - Arya Chandran
- EYES ON SERBIA: Opposition Politicians and Students are Plotting Secret Coup and CIVIL WAR â With Likely Outside Assistance â Starting with Saturdayâs Protest â PLANNING SESSIONS CAUGHT ON AUDIO - MeighTimbol
- How To Make Your Children Millionaires Before They Leave Home - Financial Samurai
- 5 Popular Medical Tests You See on Social MediaâAnd Whether You Really Need Them - Kristen Fischer
- MASSACRE IN GUAYAQUIL! 22 people brutally murdered by criminal gangs. - MeighTimbol

Nothing Budget Phones: Worth the Hype? ft. Phone 3A
- The Leftâs Hypocrisy About the âImperial Presidencyâ - Francis P. Sempa
- End of Life: Gemini will completely replace Google Assistant later this year - Ryan Whitwam
- âLeaving Neverland 2â Director Details Thousands Of Death Threats From Michael Jackson Fans - Caroline Frost
- The Crimean Warâs Lessons for War and Peace in Ukraine - Dan McLaughlin
- 7 Ways to Effectively Alleviate Stomach Gas - Cristina Mutchler
- Friends Sight Gag Is The Funniest Joke In The Series - Robert Scucci